University of Minnesota
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT00177021
We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Minneapolis, Minnesota, 55455, United States
Ten patients with extensive scalp alopecia areata (>95% hair loss)of less than 2 years duration will be invited to participate in this study. For six months each person will be asked to apply Aldara Cream 5% daily to the right half of the scalp. No drug will be applied to the left side. Skin biopsies will be taken of the right scalp before and at the completion of the therapy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hordinsky, Maria K., MD
Indiv
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07645430
Alopecia, Alopecia Areata
Banhā, Egypt
View Trial DetailsNCT05391178
Alopecia, Alopecia Areata
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03570749
Alopecia, Alopecia Areata
Birmingham, Alabama, United States
View Trial DetailsNCT04006457
Alopecia, Alopecia Areata
Birmingham, Alabama, United States
View Trial Details